Silexion Therapeutics' Latest Data Demonstrates that Subcutaneously Administered SIL204 Reduces Both Primary Tumors and Metastases in Clinically Relevant Orthotopic Models Where Human Pancreatic ...

Silexion Therapeutics Corp. has announced a strategic partnership with Catalent to advance the development of its RNA interference therapy, SIL204, aimed at treating KRAS-driven cancers.

Shares of Silexion Therapeutics Corp (NASDAQ:SLXN – Get Free Report) shot up 46.5% during mid-day trading on Wednesday .The company traded as high as $1.29 and last traded at $1.03. 66,915,194 ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Grand Cayman, Cayman Islands, April 23, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

GRAND CAYMAN - Silexion Therapeutics Corp. (NASDAQ:SLXN), a micro-cap biotech firm with a market capitalization of $5.92 million focusing on RNA interference therapies for KRAS-driven cancers, ...

Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...